<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>366</serviceExecutionTime><Drug id="25002"><DrugName>CS-891B</DrugName><DrugSynonyms><Name><Value>CS-891B</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19658">Sankyo Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="19658">Sankyo Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="25002" type="Drug"><TargetEntity id="274277" type="siDrug">Lapisteride</TargetEntity></SourceEntity><SourceEntity id="19658" type="Company"><TargetEntity id="5000284515" type="organizationId">Sankyo Co Ltd Pharmaceutical</TargetEntity></SourceEntity><SourceEntity id="13" type="ciIndication"><TargetEntity id="10001760" type="MEDDRA"></TargetEntity><TargetEntity id="D000505" type="MeSH"></TargetEntity><TargetEntity id="-1648289448" type="omicsDisease"></TargetEntity><TargetEntity id="469" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="458" type="Action"><TargetEntity id="494" type="Mechanism">Steroid 5alpha-Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="13">Alopecia</Indication></IndicationsSecondary><ActionsPrimary><Action id="458">5-Alpha-reductase inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-21T05:04:08.000Z</LastModificationDate><ChangeDateLast>2003-01-29T10:53:56.000Z</ChangeDateLast><AddedDate>1999-08-26T11:07:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19658" linkType="Company"&gt;Sankyo Co Ltd&lt;/ulink&gt; was developing &lt;ulink linkID="25002" linkType="Drug"&gt;CS-891B&lt;/ulink&gt; for the potential treatment of alopecia. As of July 1999, phase II trials were ongoing in the US and Europe [&lt;ulink linkID="337999" linkType="reference"&gt;337999&lt;/ulink&gt;]; however by June 2001, the development of &lt;ulink linkID="25002" linkType="Drug"&gt;CS-891B&lt;/ulink&gt; had been discontinued [&lt;ulink linkID="477245" linkType="reference"&gt;477245&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-06-30T00:00:00.000Z</StatusDate><Source id="477245" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-06-30T00:00:00.000Z</StatusDate><Source id="477245" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19658">Sankyo Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-08-26T00:00:00.000Z</StatusDate><Source id="337999" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19658">Sankyo Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="13">Alopecia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-08-26T00:00:00.000Z</StatusDate><Source id="337999" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01831"><Name>5-Alpha-reductase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>7 references added [&lt;ulink url="utility.reference?i_reference_id=401552" linkType="reference" linkID="401552"&gt;401552&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=477408" linkType="reference" linkID="477408"&gt;477408&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=477245" linkType="reference" linkID="477245"&gt;477245&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=403623" linkType="reference" linkID="403623"&gt;403623&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=402298" linkType="reference" linkID="402298"&gt;402298&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=415750" linkType="reference" linkID="415750"&gt;415750&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=337999" linkType="reference" linkID="337999"&gt;337999&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>